OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn's disease (CD) using a meta-analysis of clinical trials. METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation. RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: -9% (-10% to -7%) for absenteeism; -22% (-26% to -18%) for presenteeism; and -25% (-30% to -20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively. CONCLUSION: Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer's perspective.
OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn's disease (CD) using a meta-analysis of clinical trials. METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation. RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: -9% (-10% to -7%) for absenteeism; -22% (-26% to -18%) for presenteeism; and -25% (-30% to -20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively. CONCLUSION:Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer's perspective.
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Edward V Loftus; Brian G Feagan; Jean-Frédéric Colombel; David T Rubin; Eric Q Wu; Andrew P Yu; Paul F Pollack; Jingdong Chao; Parvez Mulani Journal: Am J Gastroenterol Date: 2008-10-03 Impact factor: 10.864
Authors: Johan Mesterton; Linus Jönsson; Sven H C Almer; Ragnar Befrits; Ingalill Friis-Liby; Stefan Lindgren Journal: Inflamm Bowel Dis Date: 2009-04-30 Impact factor: 5.325
Authors: Andrew Peng Yu; Louis A Cabanilla; Eric Qiong Wu; Parvez M Mulani; Jingdong Chao Journal: Curr Med Res Opin Date: 2008-02 Impact factor: 2.580
Authors: Emma Paulides; Charlotte Daker; Chris Frampton; Richard B Gearry; Tim Eglinton; Nanne K H de Boer; Charles N Bernstein; Andrew M McCombie Journal: Inflamm Intest Dis Date: 2020-03-13
Authors: Niels Teich; Harald Grümmer; Eric Jörgensen; Thomas Liceni; Frank Holtkamp-Endemann; Tim Fischer; Susanne Hohenberger Journal: BMC Gastroenterol Date: 2021-04-12 Impact factor: 3.067
Authors: Viviano Benedini; Nicola Caporaso; Gino Roberto Corazza; Zaccaria Rossi; Giovanni Fornaciari; Mario Cottone; Giorgio Frosini; Mauro Caruggi; Chiara Ottolini; Giorgio L Colombo Journal: Clinicoecon Outcomes Res Date: 2012-07-24
Authors: Simon Travis; Brian G Feagan; Laurent Peyrin-Biroulet; Remo Panaccione; Silvio Danese; Andreas Lazar; Anne M Robinson; Joel Petersson; Brandee L Pappalardo; Mareike Bereswill; Naijun Chen; Song Wang; Martha Skup; Roopal B Thakkar; Jingdong Chao Journal: J Crohns Colitis Date: 2017-10-27 Impact factor: 9.071
Authors: Åsa H Everhov; Michael C Sachs; Jonas F Ludvigsson; Hamed Khalili; Johan Askling; Martin Neovius; Pär Myrelid; Jonas Halfvarson; Caroline Nordenvall; Jonas Söderling; Ola Olén Journal: Clin Epidemiol Date: 2020-03-10 Impact factor: 4.790